...
首页> 外文期刊>Infection >Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)
【24h】

Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)

机译:慢性肾病患者丙型肝炎病毒感染的管理:意大利内科(SIMI)肝(AISF)研究肝(AISF)联合委员会的立场声明(SIMI),意大利传染病学会(SIMIT )和意大利肾脏学会(SIN)

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.
机译:由于肝脏表现出的发生,丙型肝炎病毒(HCV)感染现在被认为是一种全身疾病。其中,肾脏受累频繁。实际上,HCV感染与蛋白尿和慢性肾病(CKD)强烈有关,对肾患者的预后产生负面影响。在过去的几年里,对HCV更具体和有效的药物的可用性大大改变了这种疾病的临床过程。这些药物可以通过降低肾脏疾病,死亡率和增加肾移植受者的移植物的存活来提供整体CKD人群中的其他优势。 HCV感染与CKD之间的严格致病和预后联系需要在参与治疗HCV感染和CKD的医疗保健专业人员之间进行持续的关系。因此,参与了意大利在意大利这种高风险人口的科学社团组织了一个联合专家小组。小组的目的是生产一种位置陈述,可以在每日临床实践中用于管理HCV感染患者的整个肾病,从保守阶段到肾置换处理(透析和移植)。分享不同专业医疗保健的具体证据的专业知识是获得关于该高级人口多学科管理模式的公共知识的第一步。陈述涵盖七个区域,包括CKD的流行病学,HCV诱导的肾小球损伤,HCV相关的肾风险,CKD患者肝病的分期,预防血液透析单元中HCV的传播,HCV感染和肾移植中HCV的管理。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号